title: Computational and Practical Aspects of Drug Repositioning.
abstract: The concept of the hypothesis-driven or observational-based expansion of the therapeutic application of drugs is very seductive. This is due to a number of factors, such as lower cost of development, higher probability of success, near-term clinical potential, patient and societal benefit, and also the ability to apply the approach to rare, orphan, and underresearched diseases. Another highly attractive aspect is that the "barrier to entry" is low, at least in comparison to a full drug discovery operation. The availability of high-performance computing, and databases of various forms have also enhanced the ability to pose reasonable and testable hypotheses for drug repurposing, rescue, and repositioning. In this article we discuss several factors that are currently underdeveloped, or could benefit from clearer definition in articles presenting such work. We propose a classification scheme-drug repositioning evidence level (DREL)-for all drug repositioning projects, according to the level of scientific evidence. DREL ranges from zero, which refers to predictions that lack any experimental support, to four, which refers to drugs approved for the new indication. We also present a set of simple concepts that can allow rapid and effective filtering of hypotheses, leading to a focus on those that are most likely to lead to practical safe applications of an existing drug. Some promising repurposing leads for malaria (DREL-1) and amoebic dysentery (DREL-2) are discussed.
authors.affiliation: 1 Translational Informatics Division, Department of Internal Medicine, University of New Mexico School of Medicine , Albuquerque, New Mexico.
authors.forename: Tudor I
authors.initials: TI
authors.lastname: Oprea
authors.affiliation: 2 European Molecular Biology Laboratory-European Bioinformatics Institute , Wellcome Trust Genome Campus, Hinxton, United Kingdom .
authors.forename: John P
authors.initials: JP
authors.lastname: Overington
mesh_terms: D000818:Animals; D000962:Antimalarials / Q000494:pharmacology / Q000627:therapeutic use; D019295:Computational Biology; D017277:Drug Approval; D004353:Drug Evaluation, Preclinical; D058492:Drug Repositioning / Q000706:statistics & numerical data / Q000639:trends*; D004358:Drug Therapy; D004404:Dysentery, Amebic / Q000188:drug therapy; D006801:Humans
chemical_list: D000962:Antimalarials